TY - JOUR
T1 - Effects of SU-13437 on serum lipids in hyperlipoproteinemic patients
AU - Weiss, Peter
AU - Dujovne, Carlos A.
AU - Margolis, Simeon
AU - Lasagna, Louis
AU - Bianchine, Joseph R.
PY - 1970/1/1
Y1 - 1970/1/1
N2 - The ability of a tetralin phenoxy isobutyrate, SU-13437, to lower serum lipids was compared with that of a matching placebo in a double-blind crossover study. Treatment with SU-13437 for 4 weeks lowered serum cholesterol by 23 per cent in hypercholesterolemic patients, and it lowered serum triglycerides by 68 per cent in hypertriglyceridemic patients. None of the patients failed to respond to treatment. Gastrointestinal upset was seen in 2 of the 29 patients, and one patient had transient elevation of serum glutamic oxaloacetic transaminase.
AB - The ability of a tetralin phenoxy isobutyrate, SU-13437, to lower serum lipids was compared with that of a matching placebo in a double-blind crossover study. Treatment with SU-13437 for 4 weeks lowered serum cholesterol by 23 per cent in hypercholesterolemic patients, and it lowered serum triglycerides by 68 per cent in hypertriglyceridemic patients. None of the patients failed to respond to treatment. Gastrointestinal upset was seen in 2 of the 29 patients, and one patient had transient elevation of serum glutamic oxaloacetic transaminase.
UR - http://www.scopus.com/inward/record.url?scp=0014704022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0014704022&partnerID=8YFLogxK
U2 - 10.1002/cpt197011190
DO - 10.1002/cpt197011190
M3 - Article
C2 - 4903694
AN - SCOPUS:0014704022
VL - 11
SP - 90
EP - 96
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
IS - 1
ER -